---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-048144"
form_type: "8-K"
ticker: "MOVE"
cik: "0001734750"
company_name: "Corvex, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:56:33.906166+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Movano Q2 net loss $6.9M; advances Ring beta tests, hypoxia study meets FDA SpO2 accuracy

## Summary
- Net loss $6.9M ($0.21/sh) vs $4.7M ($0.15/sh) in Q2 2021; no revenue as development-stage company.
- Cash $21.3M at June 30, 2022, down from $33.6M at Dec 31, 2021.
- Plans DTC launch of Movano Ring in H1 2023; beta partners include Stanford, major pharma, diabetes device firm.
- Hypoxia study with UCSF: Ring achieved 2% SpO2 error margin (FDA requires 4%); larger pivotal study planned.
- Two new patents granted for SoC; planning BP and glucose clinical studies in Q3 2022.

## SEC filing metadata
- accession: 0001213900-22-048144
- form_type: 8-K
- ticker: MOVE
- cik: 0001734750
- company_name: Corvex, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1734750/000121390022048144/0001213900-22-048144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1734750/000121390022048144/ea164341-8k_movanoinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-048144
- JSON: https://secwatch.observer/filing/0001213900-22-048144.json
- Plain text: https://secwatch.observer/filing/0001213900-22-048144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.